Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments: World Market

Table of Contents

Chapter One: Executive Summary

• Overview
• Market Size and Growth
• Markets by Geographical Segments
  • U.S. Market
  • European Market
  • Japanese Market
  • ROW Market
• Market Data by Indication
• Competitive Analysis
• Scope and Methodology

Chapter Two: Introduction

• Overview
  • Monoclonal Antibodies
  • Interleukins/Interferons
  • Vaccines
  • Other Biotherapy
    • Antisense Oligonucleotides
    • Apoptosis
    • Growth Factors
    • Methylation
    • P53
    • Ras Protein Drugs
    • Regulatory Enzymes
• Description of Products
  • Monoclonal Antibodies
    • Avastin (bevacizumab)
    • Campath (alemtuzumab)
    • Erbitux (cetuximab)
    • Herceptin (trastuzumab)
    • Mylotarg (gemtuzumab ozogamicin)
    • Panorex (edrecolomab)
    • Rituxan (rituximab)
  • Interleukins/Interferons
    • Alferon-N
    • Infergen
    • Intron A
    • Proleukin
    • Roferon A
  • Vaccines
    • Gardasil
    • M-Vax
    • Melacine
    • OncoTICE
    • OncoVax
    • Pacis
    • TheraCys (ImmuCyst)
  • Other Biotherapy
    • Enzyme Adenosine Deaminase
    • Tyrosine Kinases
    • Proteasome Inhibitors
• Newly Approved Immunotherapy Drugs

Chapter Three: Research and Development

• Pipeline For BioTherapeutic/Immunologic Treatments
• Avastin
• Cervarix
• Dimericine
• Genta
• Junovan
• Tykerb
• M-Vax
• Panitumumab
• Provenge
• Tasigna
• Atrasentan (Xinlay)
• Rituxan
• Advexin
• Allovectin-7
• Alvocidib
• Insegia
• Affinitak
• AMG 162
• Anti-gastrin Immunogen G17DT
• Avicine
• BAY 43-9006 (Nexavar)
• Biovaxid
• Ceplene
• Cintredekin
• Cloretazine
• CoFactor (ANX-510)
• Cotara
• DCVax
• Enzastaurin
• Erbitux
• FavId
• Glufosfamide
• GMK vaccine
• G-Top 99 / MyVax Personalized Immunotherapy
• GVAX vaccine for prostate cancer
• HuMax-CD4 (zanolimumab)
• Ipilimumab
• Iressa
• Ixabepilone
• Javlor
• Neovastat
• Onconase
• Oncophage
• OncoVAX
• OvaRex
• PANVAC-VF
• PEG-Intron
• PF-3512676
• Phenoxodiol
• PTK787/ZK 222584
• Rencarex
• Romidepsin
• Tarceva (erlotinib)
• Telcyta A GST P1-1
• Temsirolimus
• Tesmilifene
• Thymitaq
• TransMID
• Urocidin
• Virulizin
• Xcytrin
• XL119
• Yondelis
• Zactima
• Stimuvax

Chapter Four: Market Data

• Market Size and Growth
• Markets by Product Type
• Markets by Geographical Segments
• U.S. Market
• European Market
• Japanese Market
• ROW Market
• Market Data by Indication
• Competitive Analysis

Chapter Five: Corporate Profiles

• Introduction
• Amgen, Inc
• Biogen IDEC, Inc
• Bristol-Myers Squibb Company/Oncology
• Genentech, Inc
• GlaxoSmithKline plc
• Merck & Company, Inc.
• Novartis Pharmaceuticals Corporation/Oncology
• Roche
• Sanofi-Aventis
• TAP Pharmaceutical Products, Inc.

Table of Exhibits

Chapter One: Executive Summary

• Figure 1-1: Immunological and Biotherapy Treatments as Percentage of Total Cancer Treatment Market, 2006 and 2011
• Figure 1-2: World Cancer Immunotherapy Market, 2006 2011
• Figure 1-3: World Cancer Immunotherapy Market Estimated Products Sales by Region, 2006
• Figure 1-4: World Cancer Immunotherapy Market Estimated Products Sales by Cancer Type, 2006

Chapter Two: Introduction

• Table 2-1: Monoclonal Antibodies
• Table 2-2: Interleukin/Interferon
• Table 2-3: Vaccines
• Table 2-4: Other Biotherapy
• Table 2-5: Newly Approved Immunotherapy/Biologic Agents

Chapter Three: Research and Development

• Table 3-1:Cancer Immunotherapy and Biotherapy Products in Late Stage Development (Product, Developer, Current Phase, Cancer Type, and Earliest Approval Date)

Chapter Four: Market Data

• Table 4-1: World Cancer Immunotherapy Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Figure 4-1: World Cancer Immunotherapy Market, 2004-2011 (in millions of dollars at the manufacturers level)
• Table 4-2: World Cancer Immunotherapy Market; Market by Product Type (Monoclonal Antibodies, Interleukins/Interferons, Vaccines and Other Biotherapy), 2004-2011
• Figure 4-2: World Cancer Immunotherapy Market Market by Product Type Revenues, 2004-2011 (in millions at the manufacturers level)
• Figure 4-3: World Cancer Immunotherapy Market Market by Product Type and Percent Distribution, 2004-2011
• Figure 4-4: World Cancer Immunotherapy Market Market by Product Type and Percent Market Share, 2006
• Figure 4-5: World Cancer Immunotherapy Market Market by Product Type and Percent Market Share, 2011
• Table 4-3: World Cancer Immunotherapy Market Estimated Products Sales by Region (U.S., Europe, Japan, Rest of World), 2004-2011 (in million of dollars at the manufacturers level) Estimated Revenues
• Figure 4-6: World Cancer Immunotherapy Market Estimated Product Sales by Region, 2004-2011 (in millions at the manufacturers level)
• Figure 4-7: World Cancer Immunotherapy Market Estimated Products Sales by Region, 2006
• Figure 4-8: World Cancer Immunotherapy Market Estimated Products Sales by Region, 2011
• Table 4-4: World Cancer Immunotherapy Market Estimated Products Sales by Cancer Type, 2006 (in million of dollars at the manufacturers level)
• Figure 4-9: World Cancer Immunotherapy Market Estimated Products Sales by Cancer Type, 2006
• Table 4-5: World Cancer Immunotherapy Market Leading Suppliers Shares by Market Revenues, Estimated 2006 and Projected 2011 (in million of dollars at the manufacturers level)
• Figure 4-10: World Cancer Immunotherapy Market Leading Suppliers Market Share, Estimated 2006
• Figure 4-11: World Cancer Immunotherapy Market Leading Suppliers Market Share, Projected 2011
• Table 4-6: World Cancer Immunotherapy Market Top Cancer Immunotherapy Products by Estimated Sales and Percent of Market, 2006 (in million of dollars at the manufacturers level)
• Figure 4-12: World Cancer Immunotherapy Market Top Cancer Immunotherapy Products by Estimated Sales and Percent of Market, 2006

Chapter Five: Corporate Profiles